QIAGEN N.V. (QGEN)
NL0015001WM6 - Common Stock
Taking everything into account, QGEN scores 5 out of 10 in our fundamental rating. QGEN was compared to 56 industry peers in the Life Sciences Tools & Services industry. While QGEN has a great profitability rating, there are some minor concerns on its financial health. QGEN is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
In the past year QGEN had a positive cash flow from operations.
Of the past 5 years QGEN 4 years were profitable.
QGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
QGEN's Return On Assets of 1.30% is fine compared to the rest of the industry. QGEN outperforms 71.43% of its industry peers.
With a decent Return On Equity value of 2.13%, QGEN is doing good in the industry, outperforming 71.43% of the companies in the same industry.
QGEN has a Return On Invested Capital of 8.01%. This is amongst the best in the industry. QGEN outperforms 83.93% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is below the industry average of 11.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.3% | ||
| ROE | 2.13% | ||
| ROIC | 8.01% |
ROA(3y)6.88%
ROA(5y)5.2%
ROE(3y)12.58%
ROE(5y)9.79%
ROIC(3y)9.15%
ROIC(5y)8.32%
1.3 Margins
Looking at the Profit Margin, with a value of 3.75%, QGEN is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
In the last couple of years the Profit Margin of QGEN has grown nicely.
The Operating Margin of QGEN (23.18%) is better than 92.86% of its industry peers.
In the last couple of years the Operating Margin of QGEN has grown nicely.
QGEN has a Gross Margin of 63.03%. This is amongst the best in the industry. QGEN outperforms 92.86% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.18% | ||
| PM (TTM) | 3.75% | ||
| GM | 63.03% |
OM growth 3Y-7.62%
OM growth 5Y3%
PM growth 3Y-3.3%
PM growth 5Y6.5%
GM growth 3Y-1.61%
GM growth 5Y-1.22%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so QGEN is still creating some value.
QGEN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for QGEN has been increased compared to 5 years ago.
QGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.06 indicates that QGEN is not in any danger for bankruptcy at the moment.
The Altman-Z score of QGEN (4.06) is better than 67.86% of its industry peers.
The Debt to FCF ratio of QGEN is 3.46, which is a good value as it means it would take QGEN, 3.46 years of fcf income to pay off all of its debts.
QGEN's Debt to FCF ratio of 3.46 is amongst the best of the industry. QGEN outperforms 82.14% of its industry peers.
QGEN has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
QGEN has a Debt to Equity ratio (0.27) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 4.06 |
ROIC/WACC1.03
WACC7.75%
2.3 Liquidity
QGEN has a Current Ratio of 1.77. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
QGEN has a Current ratio of 1.77. This is in the lower half of the industry: QGEN underperforms 66.07% of its industry peers.
A Quick Ratio of 1.46 indicates that QGEN should not have too much problems paying its short term obligations.
QGEN has a Quick ratio (1.46) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.46 |
3. Growth
3.1 Past
The earnings per share for QGEN have decreased by -1.71% in the last year.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 9.58% yearly.
QGEN shows a decrease in Revenue. In the last year, the revenue decreased by -1.90%.
QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.53% yearly.
EPS 1Y (TTM)-1.71%
EPS 3Y-0.51%
EPS 5Y9.58%
EPS Q2Q%4.61%
Revenue 1Y (TTM)-1.9%
Revenue growth 3Y1.66%
Revenue growth 5Y5.53%
Sales Q2Q%0.3%
3.2 Future
QGEN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.75% yearly.
The Revenue is expected to grow by 6.29% on average over the next years.
EPS Next Y3.31%
EPS Next 2Y4.94%
EPS Next 3Y6.44%
EPS Next 5Y7.75%
Revenue Next Year0.95%
Revenue Next 2Y3.49%
Revenue Next 3Y4.56%
Revenue Next 5Y6.29%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 21.13, the valuation of QGEN can be described as rather expensive.
QGEN's Price/Earnings ratio is rather cheap when compared to the industry. QGEN is cheaper than 96.43% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 31.52. QGEN is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 18.85, the valuation of QGEN can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 87.50% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.55. QGEN is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.13 | ||
| Fwd PE | 18.85 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, QGEN is valued cheaper than 94.64% of the companies in the same industry.
85.71% of the companies in the same industry are more expensive than QGEN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.28 | ||
| EV/EBITDA | 15.14 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
QGEN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)6.39
PEG (5Y)2.21
EPS Next 2Y4.94%
EPS Next 3Y6.44%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.00%, QGEN has a reasonable but not impressive dividend return.
QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.64. QGEN pays more dividend than 100.00% of the companies in the same industry.
QGEN's Dividend Yield is a higher than the S&P500 average which is at 2.22.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y4.94%
EPS Next 3Y6.44%
QIAGEN N.V.
NYSE:QGEN (10/14/2024, 11:13:21 AM)
43.95
+0.03 (+0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.84B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.13 | ||
| Fwd PE | 18.85 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)6.39
PEG (5Y)2.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.3% | ||
| ROE | 2.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 23.18% | ||
| PM (TTM) | 3.75% | ||
| GM | 63.03% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-1.71%
EPS 3Y-0.51%
EPS 5Y
EPS Q2Q%
EPS Next Y3.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.9%
Revenue growth 3Y1.66%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y